AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention

Loading news article.

AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention | WAPE

AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention

Article summary

Related companies

Comments —